Ad
related to: drugmaker eli lilly
Search results
1 No-Brainer Growth Stock to Buy and Hold | The Motley Fool
The Motley Fool· 3 days agoLilly's (LLY -1.50%) performance in recent years as it has delivered market-crushing returns and...
Lilly girding for questions over Alzheimer's treatment from FDA committee - Indianapolis Business...
Indianapolis Business Journal· 19 hours agoIt’s been a roller-coaster ride for three decades at Eli Lilly and Co. in trying to develop a...
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
CNBC· 6 days agoNovo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but...
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Reuters via Yahoo Finance· 4 days agoCipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO ...
What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and...
CNN via Yahoo News· 4 hours agoNew analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on...
Alzheimer’s vaccine licensing deal boosts AC Immune
Market Watch· 13 hours agoThe deal gives Japanese drugmaker Takeda the exclusive option to license global rights to the vaccine, known as ACI-24.060, which is designed to delay or...
FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug
Market Watch· 6 days agoEli Lilly on Tuesday said the U.S. Food and Drug Administration has set June 10 as the date for its advisory committee meeting on the drugmaker ...
How A Top Fund Beats The Market By Owning Future Leaders
Investor's Business Daily· 4 days agoBut they also hold large positions in cloud-computing leader Microsoft and innovative drugmaker Eli ...
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Reuters· 2 hours ago, opens new tab popular Wegovy obesity treatment maintained an average of 10% weight loss after four...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
BioPharma Dive via Yahoo Finance· 14 hours agoThe deal — worth $100 million up front and potentially billions more later on — gives Takeda an...
